Allakos Inc

Allakos — Corporate Update (March 2020)

40 slides from Allakos's corporate update, Mar 24, 2020

  1. Slide 1: Corporate Update March 2020

    Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Corporate Update March 2020 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b

  3. Slide 3: Agenda

    Agenda Robert Alexander, PhD Overview 5:00 – 5:20 PM Henrik Rasmussen, MD PhD Initiated clinical studies MGID Phase 1 study results 5:20 – 5:50 PM Q&A 5:50 – 6:00 PM

  4. Slide 4: Overview

    Overview Robert Alexander, PhD CEO – Allakos

  5. Slide 5: Executive Summary

    Executive Summary Recently initiated Phase 3 study in Eosinophilic Gastritis (EG) and/or Eosinophilic Duodenitis (EoD; previously referred to as EGE) Recently initiated Phase 2/3 study in Eosinophilic Esophagitis (EoE) First group of subjects dosed in Phase 1 subcutaneous healthy volunteer study Pos

  6. Slide 6: Impact of Coronavirus on Allakos Clinical Trials

    Impact of Coronavirus on Allakos Clinical Trials Phase 3 EG/EoD and Phase 2/3 EoE sites have been activated and potential patients have been identified To avoid study disruption, we have decided to delay enrollment in the Phase 3 EG/EoD and the Phase 2/3 EoE studies Current estimated completion of H

  7. Slide 7: Antolimab (AK002) Targets Siglec-8 on Mast Cells and Eosinophils

    Antolimab (AK002) Targets Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response Antolimab Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis Antolimab

  8. Slide 8: Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease

    Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease

  9. Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases

    Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Duodenitis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTESTINAL

  10. Slide 10: Eosinophilic Gastrointestinal Diseases (EGIDs)

    Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Duodenitis (EoD) = US Prevalence ~20-25K ~25K ~200K EG, EoD, EoE Chronic Eosinophilic Inflammation of the Stomach, Duodenum, or Esophagus Eosinophils and

  11. Slide 11: EGID Biopsies Have Elevated Eosinophils & Mast Cells

    EGID Biopsies Have Elevated Eosinophils & Mast Cells Source: Youngblood B, et al. JCI Insights. 2019 Eosinophils 10 8 6 4 2 0 Mast Cells 15 10 5 0 Mast Cells 12 8 4 0 Eosinophils 12 8 4 0 % of CD45+ Viable Cells Esophagus Stomach Normal EoE Normal EoE Normal EG Normal EG *p<0.05

  12. Slide 12: Eos and Mast Cells Are Activated in EGID Biopsies

    Eos and Mast Cells Are Activated in EGID Biopsies CD63 3000 2000 1000 0 150000 100000 50000 0 IgE 8000 4000 2000 0 6000 CD49d 60000 40000 20000 0 CD11b Eosinophils Mast Cells Normal EG Normal EG Normal EG Normal EG Source: Youngblood B, et al. JCI Insights. 2019 *p<0.05 Eosinophils and mast cells bo

  13. Slide 13: End of Phase 2 (ENIGMA) Meeting Summary

    End of Phase 2 (ENIGMA) Meeting Summary

  14. Slide 14: Key Takeaways

    Key Takeaways Histologic Co-Primary Endpoint Consistent with EoE guidance, FDA recommended using a responder analysis Histologic response thresholds set at ≤4 eos/hpf in the stomach and/or ≤15 eos/hpf in the duodenum Symptom Co-Primary Endpoint The same PRO questionnaire will be used in Phase 3 as w

  15. Slide 15: Phase 3 EG/EoD Study Design

    Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formally referred to as EGE) Study Design Henrik S. Rasmussen, MD PhD Chief Medical Officer – Allakos

  16. Slide 16: Phase 3 Eosinophilic Gastritis and/or Duodenitis Study

    Phase 3 Eosinophilic Gastritis (EG) and/or Duodenitis (EoD) Study Study Design Multi-center, randomized, double-blind, placebo-controlled study in EG/EoD Adult patients with active moderate to severe symptoms Biopsy confirmed EG/EoD Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs, and/or Duodenu

  17. Slide 17: Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA

    Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA Abdominal pain Nausea Early satiety Vomiting Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the symptoms of EG/EoD patients on a daily basis Measures symptoms

  18. Slide 18: Phase 3 EG/EoD Endpoints

    Phase 3 EG/EoD Endpoints Histologic Co-Primary Endpoint Proportion of responders: Stomach: ≤4 eos/hpf in 5 hpfs, and/or Duodenum: ≤15 eos/hpf in 3 hpfs Symptom Co-Primary Endpoint Absolute change in patient reported TSS-6 Key Secondary Endpoints Percent change in tissue eosinophils Treatment respond

  19. Slide 19: Phase 2 ENIGMA Results Analyzed Against Phase 3 Endpoints (ITT)

    Phase 2 ENIGMA Results Analyzed Against Phase 3 Endpoints (ITT) Co-Primary Endpoints Antolimab Placebo p – value 3 mg/kg Histologic Endpoint1 Proportion of Responders 95% 0% <0.0001 Symptom Endpoint2 Mean Absolute Change in TSS-6 -16.6 -8.1 0.0162 Mean Percent Change in TSS-6 -59% -27% 0.0033 1Respo

  20. Slide 20: Phase 2/3 Eosinophilic Esophagitis (EoE) Study Design

    Phase 2/3 Eosinophilic Esophagitis (EoE) Study Design

  21. Slide 21: Phase 2/3 Eosinophilic Esophagitis (EoE) Study

    Phase 2/3 Eosinophilic Esophagitis (EoE) Study Study Design Multi-center, randomized, double-blind, placebo-controlled study in Eosinophilic Esophagitis Patients (12 to 80 years old) with active moderate to severe symptoms Biopsy confirmed EoE Esophagus: ≥15 eos in 1 hpf 300 Patients – 3 arms 100 pa

  22. Slide 22: Phase 2/3 Eosinophilic Esophagitis Endpoints

    Phase 2/3 Eosinophilic Esophagitis Endpoints Histologic Co-Primary Endpoint Proportion of responders: ≤6 eos/hpf in 1 hpf in the esophagus Symptom Co-Primary Endpoint Absolute change in patient reported Dysphagia Symptom Questionnaire (DSQ) Key Secondary Endpoints Percent change in esophageal tissue

  23. Slide 23: Phase 1 Subcutaneous Healthy Volunteer Study

    Phase 1 Subcutaneous Healthy Volunteer Study

  24. Slide 24: Phase 1 Subcutaneous Healthy Volunteer Study

    Phase 1 Subcutaneous Healthy Volunteer Study Study Design Phase 1 single-dose, placebo-controlled study 50 healthy volunteers Doses assessed: SC: Antolimab 0.3, 1.0, 3.0, 5.0 mg/kg and placebo IV: Antolimab 1.0, 3.0 mg/kg Data available: Q4 2020

  25. Slide 25: Mast Cell Gastrointestinal Disease (MGID)

    Mast Cell Gastrointestinal Disease (MGID) Patients with Chronic GI Symptoms and Elevated Mast Cells

  26. Slide 26: ENIGMA Screening Patient Distribution

    ENIGMA Screening Patient Distribution Met Symptom Criteria n=88 Entered Screening n=113 16 of 88 symptomatic patients had elevated mast cells only EG / EoD n=72 Mast Cell GI Disease n=16 MGID: ≥30 Mast Cells EG/EoD: ≥30 Eos & Mast Cells1 165 met all enrollment criteria for ENIGMA; 1 patient had elev

  27. Slide 27: Phase 1 Mast Cell GI Disease (MGID) Study

    Phase 1 Mast Cell GI Disease (MGID) Study Study Design Multi-center, open-label, multi-dose, Phase 1 study Active moderate to severe symptoms as measured by PRO used in ENIGMA N=7 patients Biopsy confirmed elevated mast cells Stomach: ≥30 mast cells/high powered field (hpf) in 5 hpfs, and/or Duodenu

  28. Slide 28: Baseline Gastrointestinal Eosinophils and Mast Cell Counts

    Baseline Gastrointestinal Eosinophils and Mast Cell Counts Mean Gastrointestinal Cells Eosinophils Mast Cells Mean Gastrointestinal Cells Eosinophils Mast Cells ENIGMA EG / EoD (n=65) MGID (n=7)

  29. Slide 29: EG/EoD and MGID Patients Have Similar Symptomatic Burden

    EG/EoD and MGID Patients Have Similar Symptomatic Burden Symptom Reported Symptom Intensity During Screening (0-10) Mean Early Satiety Bloating Abdominal Pain Abdominal Cramping Loss of Appetite Nausea Diarrhea Vomiting EG/EoD patients (n=65) MGID Patients (n=7)

  30. Slide 30: 64% Improvement in Total Symptom Score

    64% Improvement in Total Symptom Score Mean % Change from BL Mean % Change from BL Antolimab 3.0 mg/kg Placebo MGID EG / EoD in ENIGMA PRO TSS-8: Change from Baseline Antolimab 3.0 mg/kg

  31. Slide 31: Improvement Across All Symptoms Measured

    Improvement Across All Symptoms Measured MGID: PRO Symptom Score Antolimab (n=7) Median Score -69% -78% -100% -90% -91% -57% -91% -85% Baseline End of Tx

  32. Slide 32: MGID: Histologic Results

    MGID: Histologic Results Median Eosinophils Cells Baseline Week 22 Median Mast Cells Baseline Week 22 -100% GI Eosinophils GI Mast Cells -18%

  33. Slide 33: MGID: Safety Summary

    MGID: Safety Summary Generally well tolerated Most common AE was infusion related reactions (IRR), all of which were mild No drug-related SAEs

  34. Slide 34: EGID & MGID Prevalence Study

    EGID & MGID Prevalence Study

  35. Slide 35: EGID & MGID Prevalence Study

    EGID & MGID Prevalence Study Study Design Multi-center study to assess prevalence of EGIDs and MGID in patients with chronic functional GI symptoms with or without diagnosis of Irritable Bowel Syndrome (IBS), Functional Dyspepsia (FD), or Chronic Gastritis Biopsies from >200 adult patients with acti

  36. Slide 36: Summary

    Summary Recently initiated Phase 3 EG/EoD and Phase 2/3 EoE studies First group dosed in subcutaneous healthy volunteer study Antolimab improves symptoms in patients with chronic GI symptoms and elevated mast cells (MGIDs) EGID & MGID prevalence study in patients with chronic functional GI disease i

  37. Slide 37: Corporate Updates

    Corporate Updates

  38. Slide 38: Strong Balance Sheet and Significant IP Protection

    Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of Dec 31, 2019 $495.9M Q4 2019 Operating Expenses $26.9M Antolimab US patents first to expire 2035 Lonza currently manufactures antolimab

  39. Slide 39: Anticipated Near-term Milestones

    Anticipated Near-term Milestones H2’20 EGID & MGID Prevalence Study Results H2’21 Phase 2/3 EoE Results* H2’20 Phase 1 Data For Subcutaneous Antolimab Q2’20 Phase 2 Extension Data in EG and/or EoD H2’21 Phase 3 EG and/or EoD Results* *Estimates subject to delay due to coronavirus

  40. Slide 40: Thank you, Q&A

    Thank you Q&A

Allakos — Corporate Update (March 2020) on 6ix